Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders

Q3 Biochemistry, Genetics and Molecular Biology

Avicenna journal of medical biotechnology Pub Date : 2024-02-06 DOI:10.18502/ajmb.v16i2.14857

Sheyda Khalilian, Zahra Mohajer, S. Ghafouri-Fard

{"title":"Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders","authors":"Sheyda Khalilian, Zahra Mohajer, S. Ghafouri-Fard","doi":"10.18502/ajmb.v16i2.14857","DOIUrl":null,"url":null,"abstract":"Coagulation factor VIII (FVIII) is an essential cofactor in the coagulation cascade, encoded by the F8 gene on the long arm of chromosome X (Xq28). FVIII is normally circulated in complex with Von Willebrand factor (VWF) and has relevant emerging extracoagulative functions. Dysregulation of FVIII is associated with tumor progression, and could be used as a novel biomarker for tumor screening and monitoring. In breast cancer, bladder cancer, colorectal carcinoma, esophageal carcinoma, hepatocellular carcinoma and lung cancer, F8 is regarded as an oncogene. In coronary heart disease, hemophilia A and liver disease, F8 dysregulation has been recognized as a potential biomarker for disease diagnosis and prognosis. However, the basis of these differential expression levels remains to be understood. In this review, which is a mixture of literature review and bioinformatics analysis we described the biological functions and characteristics of FVIII, and also its expression level in non-malignant disorders and various cancers. ","PeriodicalId":8669,"journal":{"name":"Avicenna journal of medical biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna journal of medical biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ajmb.v16i2.14857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Coagulation factor VIII (FVIII) is an essential cofactor in the coagulation cascade, encoded by the F8 gene on the long arm of chromosome X (Xq28). FVIII is normally circulated in complex with Von Willebrand factor (VWF) and has relevant emerging extracoagulative functions. Dysregulation of FVIII is associated with tumor progression, and could be used as a novel biomarker for tumor screening and monitoring. In breast cancer, bladder cancer, colorectal carcinoma, esophageal carcinoma, hepatocellular carcinoma and lung cancer, F8 is regarded as an oncogene. In coronary heart disease, hemophilia A and liver disease, F8 dysregulation has been recognized as a potential biomarker for disease diagnosis and prognosis. However, the basis of these differential expression levels remains to be understood. In this review, which is a mixture of literature review and bioinformatics analysis we described the biological functions and characteristics of FVIII, and also its expression level in non-malignant disorders and various cancers.

查看原文本刊更多论文

因子 VIII 是人类癌症和其他疾病诊断、预后和治疗预测的新型生物标记物

凝血因子 VIII（FVIII）是凝血级联过程中必不可少的辅助因子，由 X 染色体长臂（Xq28）上的 F8 基因编码。FVIII 通常与冯-威廉因子（Von Willebrand factor，VWF）复合物一起循环，并具有新出现的相关凝血外功能。FVIII 的失调与肿瘤进展有关，可用作肿瘤筛查和监测的新型生物标记物。在乳腺癌、膀胱癌、结直肠癌、食管癌、肝细胞癌和肺癌中，F8 被认为是一种致癌基因。在冠心病、血友病 A 和肝病中，F8 的失调被认为是疾病诊断和预后的潜在生物标志物。然而，这些不同表达水平的基础仍有待了解。在这篇文献综述和生物信息学分析相结合的文章中，我们描述了 FVIII 的生物学功能和特点，以及它在非恶性疾病和各种癌症中的表达水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Avicenna journal of medical biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

2.90

自引率

0.00%

发文量